• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

无包衣片中三氯苯达唑制剂与控制的质量源于设计方法:从多晶型物到药物制剂

A QbD Approach for the Formulation and Control of Triclabendazole in Uncoated Tablets: From Polymorphs to Drug Formulation.

作者信息

Muzi Lucas P, Antonio Marina, Maggio Rubén M

机构信息

Área de Análisis de Medicamentos, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario and Instituto de Química Rosario (IQUIR, CONICET-UNR), Suipacha 531, Rosario S2002LRK, Argentina.

出版信息

Pharmaceutics. 2024 Dec 13;16(12):1594. doi: 10.3390/pharmaceutics16121594.

DOI:10.3390/pharmaceutics16121594
PMID:39771572
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11679758/
Abstract

Triclabendazole (TCB) is a well-established anthelmintic effective in treating fascioliasis, a neglected tropical disease. This study employs quality by design (QbD) to investigate the impact of TCB polymorphism and pharmacotechnical variables, from the development of immediate-release tablets to process optimization and green analysis. Critical process parameters (CPPs) and critical material attributes (CMAs), characterized by type of polymorph, composition of excipients (talc, lactose, cornstarch, and magnesium stearate), and compression force, were screened using a Plackett-Burman design (n = 24), identifying polymorphic purity and cornstarch as a CPP. To establish a mathematical model linking CPP to dissolution behaviour, a multiple linear regression (MLR) was applied to the training design (central composite design, n = 18). Simultaneously, a near-infrared spectroscopy coupled to partial least squares (NIR-PLSs) method was developed to analyze CPPs. An independent set of samples was prepared and analyzed using the NIR-PLSs model, and their dissolution profiles were also obtained. The PLSs model successfully predicted the CPPs in the new samples, yielding almost quantitative results (100 ± 3%), and MLR dissolution predictions mirrored the actual dissolution profiles (f2 = 85). In conclusion, the developed model could serve as a comprehensive tool for the development and control of pharmaceutical formulations, starting from the polymorphic composition and extending to achieve targeted dissolution outcomes.

摘要

三氯苯达唑(TCB)是一种成熟的驱虫药,对治疗被忽视的热带病肝片吸虫病有效。本研究采用质量源于设计(QbD)方法,从速释片的研发到工艺优化及绿色分析,考察TCB多晶型及制药工艺变量的影响。采用Plackett-Burman设计(n = 24)筛选关键工艺参数(CPPs)和关键物料属性(CMAs),其特征包括多晶型类型、辅料(滑石粉、乳糖、玉米淀粉和硬脂酸镁)组成及压片力,确定多晶型纯度和玉米淀粉为CPP。为建立CPP与溶出行为的数学模型,对训练设计(中心复合设计,n = 18)应用多元线性回归(MLR)。同时,开发了一种近红外光谱结合偏最小二乘法(NIR-PLSs)的方法来分析CPPs。制备了一组独立的样品,使用NIR-PLSs模型进行分析,并获得其溶出曲线。PLSs模型成功预测了新样品中的CPPs,得到了几乎定量的结果(100±3%),MLR溶出预测反映了实际溶出曲线(f2 = 85)。总之,所开发的模型可作为药物制剂研发和控制的综合工具,从多晶型组成开始,延伸至实现靶向溶出结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec11/11679758/f7a144490823/pharmaceutics-16-01594-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec11/11679758/abd1a697b4e1/pharmaceutics-16-01594-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec11/11679758/848a4e5df9d7/pharmaceutics-16-01594-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec11/11679758/68779c4f3eb3/pharmaceutics-16-01594-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec11/11679758/7e5529fe7ca4/pharmaceutics-16-01594-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec11/11679758/d0b1e2cebd10/pharmaceutics-16-01594-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec11/11679758/f7a144490823/pharmaceutics-16-01594-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec11/11679758/abd1a697b4e1/pharmaceutics-16-01594-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec11/11679758/848a4e5df9d7/pharmaceutics-16-01594-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec11/11679758/68779c4f3eb3/pharmaceutics-16-01594-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec11/11679758/7e5529fe7ca4/pharmaceutics-16-01594-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec11/11679758/d0b1e2cebd10/pharmaceutics-16-01594-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec11/11679758/f7a144490823/pharmaceutics-16-01594-g006.jpg

相似文献

1
A QbD Approach for the Formulation and Control of Triclabendazole in Uncoated Tablets: From Polymorphs to Drug Formulation.无包衣片中三氯苯达唑制剂与控制的质量源于设计方法:从多晶型物到药物制剂
Pharmaceutics. 2024 Dec 13;16(12):1594. doi: 10.3390/pharmaceutics16121594.
2
Assessment of mefenamic acid polymorphs in commercial tablets using chemometric coupled to MIR and NIR spectroscopies. Prediction of dissolution performance.采用化学计量学结合 MIR 和 NIR 光谱法对市售片剂中的甲芬那酸多晶型体进行评估。预测溶出性能。
J Pharm Biomed Anal. 2018 Feb 5;149:603-611. doi: 10.1016/j.jpba.2017.11.053. Epub 2017 Nov 28.
3
Industrial application of QbD and NIR chemometric models in quality improvement of immediate release tablets.质量源于设计(QbD)和近红外光谱化学计量学模型在速释片质量改进中的工业应用
Saudi Pharm J. 2021 Jun;29(6):516-526. doi: 10.1016/j.jsps.2021.04.012. Epub 2021 Apr 22.
4
Implementation of quality by design approach in manufacturing process optimization of dry granulated, immediate release, coated tablets - a case study.质量源于设计方法在干法制粒速释包衣片制造工艺优化中的应用——案例研究
Drug Dev Ind Pharm. 2017 Oct;43(10):1626-1636. doi: 10.1080/03639045.2017.1328431. Epub 2017 May 23.
5
Enabling real time release testing by NIR prediction of dissolution of tablets made by continuous direct compression (CDC).通过近红外(NIR)预测连续直接压缩(CDC)制粒片剂的溶出度,实现实时释放测试。
Int J Pharm. 2016 Oct 15;512(1):96-107. doi: 10.1016/j.ijpharm.2016.08.033. Epub 2016 Aug 16.
6
Development of immediate release Rupatadine fumarate 10 mg tablets: A Quality by Design (QbD) approach.富马酸卢帕他定 10mg 普通片的研制:基于质量源于设计(QbD)的方法。
Drug Dev Ind Pharm. 2019 Oct;45(10):1674-1681. doi: 10.1080/03639045.2019.1652637. Epub 2019 Aug 30.
7
Implementation of Quality by Design (QbD) for development of bilayer tablets.质量源于设计(QbD)在双层片开发中的应用
Eur J Pharm Sci. 2023 May 1;184:106412. doi: 10.1016/j.ejps.2023.106412. Epub 2023 Feb 22.
8
Quality by design-based development and in vitro evaluation of dual release tablet of etoricoxib and thiocolchicoside: A novel chronotherapeutic approach for arthritis pain management.基于质量源于设计的依托考昔和硫代秋水仙碱双层片的开发及体外评价:关节炎疼痛管理的一种新的时辰治疗方法。
Ann Pharm Fr. 2024 Nov;82(6):1103-1117. doi: 10.1016/j.pharma.2024.07.004. Epub 2024 Jul 11.
9
Development and in vitro evaluation of pH-independent release matrix tablet of weakly acidic drug valsartan using quality by design tools.采用质量源于设计工具研制和体外评价弱酸性药物缬沙坦的 pH 非依赖性释放骨架片。
Drug Dev Ind Pharm. 2018 Dec;44(12):1905-1917. doi: 10.1080/03639045.2018.1496450. Epub 2018 Sep 10.
10
[Identification of CMAs of Jianwei Xiaoshi Tablet granules based on QbD concept and construction of their predictive model].基于质量源于设计理念的健胃消食片颗粒临界相对湿度的测定及其预测模型构建
Zhongguo Zhong Yao Za Zhi. 2024 Dec;49(24):6565-6573. doi: 10.19540/j.cnki.cjcmm.20241022.301.

本文引用的文献

1
Ritonavir Form III: A New Polymorph After 24 Years.利托那韦晶型 III:24 年后的一种新多晶型物。
J Pharm Sci. 2023 Jan;112(1):237-242. doi: 10.1016/j.xphs.2022.09.026. Epub 2022 Oct 1.
2
Biorelevant dissolution testing and physiologically based absorption modeling to predict in vivo performance of supersaturating drug delivery systems.生物相关溶出试验和基于生理的吸收建模预测超饱和药物传递系统的体内性能。
Int J Pharm. 2021 Sep 25;607:120958. doi: 10.1016/j.ijpharm.2021.120958. Epub 2021 Jul 29.
3
Triclabendazole for the treatment of fascioliasis.
三氯苯达唑治疗片形吸虫病。
Drugs Today (Barc). 2019 Dec;55(12):743-752. doi: 10.1358/dot.2019.55.12.3058861.
4
Improving the Dissolution of Triclabendazole from Stable Crystalline Solid Dispersions Formulated for Oral Delivery.提高稳定结晶固体分散体中三氯苯达唑的溶出度,用于口服给药。
AAPS PharmSciTech. 2019 Dec 5;21(1):16. doi: 10.1208/s12249-019-1551-4.
5
Triclabendazole in the treatment of human fascioliasis: a review.三氯苯达唑治疗人体片形吸虫病:综述。
Trans R Soc Trop Med Hyg. 2019 Dec 1;113(12):797-804. doi: 10.1093/trstmh/trz093.
6
Chitosan-based nanodelivery systems applied to the development of novel triclabendazole formulations.壳聚糖基纳米递药系统在新型三氯苯达唑制剂开发中的应用。
PLoS One. 2018 Dec 12;13(12):e0207625. doi: 10.1371/journal.pone.0207625. eCollection 2018.
7
Power of the Dissolution Test in Distinguishing a Change in Dosage Form Critical Quality Attributes.溶出试验在鉴别剂型关键质量属性变化中的作用。
AAPS PharmSciTech. 2018 Nov;19(8):3328-3332. doi: 10.1208/s12249-018-1197-7. Epub 2018 Oct 22.
8
First phenotypic and genotypic description of Fasciola hepatica infecting highland cattle in the state of Mexico, Mexico.墨西哥墨西哥州高海拔牛感染肝片形吸虫的第一表型和基因型描述。
Infect Genet Evol. 2018 Oct;64:231-240. doi: 10.1016/j.meegid.2018.06.032. Epub 2018 Jul 2.
9
Assessment of mefenamic acid polymorphs in commercial tablets using chemometric coupled to MIR and NIR spectroscopies. Prediction of dissolution performance.采用化学计量学结合 MIR 和 NIR 光谱法对市售片剂中的甲芬那酸多晶型体进行评估。预测溶出性能。
J Pharm Biomed Anal. 2018 Feb 5;149:603-611. doi: 10.1016/j.jpba.2017.11.053. Epub 2017 Nov 28.
10
Evaluation of a biphasic in vitro dissolution test for estimating the bioavailability of carbamazepine polymorphic forms.用于评估卡马西平多晶型物生物利用度的双相体外溶出试验的评价
Eur J Pharm Sci. 2017 Jul 15;105:64-70. doi: 10.1016/j.ejps.2017.05.013. Epub 2017 May 6.